Suzhou Connect Biopharma Gains Rights to Arena’s Anti-Inflammatory Drugs

Suzhou Connect Biopharmaceuticals, Ltd. gained control of two series of anti-inflammatory compounds from Arena Pharma of San Diego. Zheng Wei, PhD, initiated development of the compounds while he was Director of Immunology at Arena, and he is now Co-founder and CEO of Suzhou Connect. Terms of the agreement were not disclosed. More details.... Stock Symbol: (NSDQ: ARNA) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});